Sandra Pohlman

Sandra Pohlman is co-founder and partner of df-mp. She heads the firm’s large and diversified biotechnology and pharmaceuticals practice group together with Dr. Dörries. A main part of her practice is oppositions and prosecution before the European Patent Office, where she has consistently obtained favorable results for her clients. Additionally, Ms. Pohlman is qualified to practice before the Unified Patent Court (UPC), the German courts and is a registered U.S. Patent Attorney.

She has served as lead counsel in notable opposition cases relating to patents for blockbuster drugs and groundbreaking technologies including, more recently, Tecfidera®, Tysabri®, and attacking and defending CRISPR patents. In IAM 1000: The World's Leading Patent Practitioners 2013-2025, Ms. Pohlman was recommended for her expertise in patent prosecution and invalidity actions including the following comments about her skills: "She displays a matchless knowledge of her law, her writing is brilliant, and she is hugely responsive", and: "She can handle high-pressure briefs with a cool head and is the first choice for North American law firms". Managing Intellectual Property lists Sandra Pohlman as IP Star for Germany in their MIP Handbook 2014-2025, and she is listed in Chambers

2021-2025, including in the Chambers Global Guide since 2024. She was listed as one of the Top 250 Women in IP (worldwide) by Managing IP in 2016-2025 and is a recognized Thought Leader-Germany-Intellectual Property in Who’s Who Legal. In 2022, Managing IP awarded her the prize of Germany’s Attorney of the Year for Patents, and in 2024, her EPO opposition team received the prestigious award for European Cross-Border Patent Litigation Team of the Year for the matter of Tecfidera versus generics.